Breast cancer
HRS-6209-205
An Open-Label, Multi-Center Phase II Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HRS-6209 in Combination with Fulvestrant or Letrozole in Patients with HR-Positive/HER2-Negative Advanced Unresectable or Metastatic Breast Cancer
Trial overview
Clinical Area
Medical Oncology
Disease
Breast
Disease site
Breast
Study Phase
II
Trial Identifiers
Registration number: NCT07358377
Principal Investigator(s)
··
··